Ractigen Therapeutics has shared promising first-in-human results on RAG-18 at WMS 2026, showcasing its potential for RNA activation in Duchenne Muscular Dystrophy.

Ractigen Therapeutics will present pioneering RNA activation data for Duchenne muscular dystrophy at the 31st World Muscle Society Congress in Hiroshima, Japan.

Ractigen Therapeutics announces groundbreaking FDA IND clearance for RAG-1C, a first-of-its-kind saRNA therapy targeting Proliferative Vitreoretinopathy, offering new hope in ocular treatment.

Ractigen Therapeutics has raised over $31 million to enhance its saRNA pipeline and proprietary delivery technologies, advancing key clinical programs.

Ractigen Therapeutics reports significant Phase I trial results for RAG-17, including an 81% reduction in a key neurodegenerative biomarker, at the AAN Annual Meeting 2026.

Ractigen Therapeutics has commenced the Phase II clinical trial of RAG-17, a novel siRNA therapy aimed at treating SOD1-ALS. The dosing of the first patient marks a significant step towards potential therapeutic advancements.

Ractigen Therapeutics debuted RAG-17's promising ALS data at AAN 2025, receiving top honors and advancing its Phase I trial for SOD1-ALS.

Dr. Long-Cheng Li, CEO of Ractigen Therapeutics, receives the 2024 Life Science Ice Breaking Award for his pioneering research in ALS treatments.

Ractigen Therapeutics has successfully dosed the first patient in a clinical trial for RAG-17 targeting ALS, marking a significant step in RNA therapy development.